Loading
A phase 3 trial of Retlirafusp alfa run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active.
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer is a phase 3 interventional study registered as NCT04950322 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 737 participants enrolled, started 2021-12-06. Conditions listed: Gastric or Gastroesophageal Junction Cancer. No results are recorded here; the registry entry is the source.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors.